The drug offered more relief than a placebo in clinical trials, though it does not appear more effective than other pain ...

Independent pharmacies across Kansas will close on Wednesday, Feb.5, for a day of advocacy to raise awareness of what they ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

FDA approves new pain pill Journavx, a non-opioid alternative to treat acute pain. Despite modest effectiveness, it shows promise in pain management.

Swiss pharmaceutical giant Novartis (NVS) on Friday reported forecast-beating quarterly sales as its clutch of heart failure to breast cancer ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

SaveHealth explores the potential prescription cost savings that can be achieved by leveraging cash prices and discount cards ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...